MedTrace Logo

The Effect Of Botox In Patients With Gummy Smile With And Without Zinc And Phytase Supplementation.

NCT06577285 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-09-23

No results posted yet for this study

Summary

Participants with esthetic concern of excessive gingival display who meets the inclusion criteria, will be carried out including history taking, clinical examination and initial therapy.

The initial therapy will consist of periodontal treatment (phase I therapy) including supragingival scaling, subgingival debridement if needed. The mechanical plaque control instructions for each patient include brushing and interdental cleaning techniques. Patients who have inadequate crown length and width ratio or short clinical crown will receive esthetic crown lengthening procedure to adjust gingival levels before being included in this study.

Patients in the intervention group I will take zinc gluconate 50 mg 1 per day to increase zinc level with phytase supplement 176mg (800FTU) 2 tablets per day to give the maximum absorption of zinc, both supplements will be given for 4 days before botulinum toxin injections. Patients in the intervention group II will take zinc gluconate 50 mg 1 per day to increase zinc level, 4 days before botulinum toxin injections.

Patients in the control group will receive the Botulinum toxin injections only Clinical photographs will be taken at baseline, 2 weeks, 1 month, 3 months postoperatively.

Conditions

  • Excessive Gingival Display

Interventions

DIETARY_SUPPLEMENT

zinc gluconate 50 mg with phytase supplement 176mg (800FTU)

zinc gluconate 50 mg1 per day with phytase supplement 176mg (800FTU) (Goodphyte company) 2 tablets per day

DIETARY_SUPPLEMENT

zinc gluconate 50 mg

zinc gluconate 50 mg 1 per day, 4 days before botulinum toxin injections.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Weam A El-Battawy, Ass. Prof. · Cairo University

  • Mawda M Hussain, Bachelor · Cairo University

  • Nesma F Shemais, lecturer · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2024-12-01
Completion
2025-06-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06577285 on ClinicalTrials.gov